| scholarly article | Q13442814 |
| P50 | author | Morie A Gertz | Q57052163 |
| P2860 | cites work | CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy | Q24649764 |
| Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. | Q31075899 | ||
| Incidence and survival in non-hereditary amyloidosis in Sweden | Q31106882 | ||
| Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis | Q33151135 | ||
| Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis | Q33161948 | ||
| Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial | Q33256792 | ||
| Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation | Q33292965 | ||
| The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis | Q33372805 | ||
| Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens | Q33508070 | ||
| Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis | Q33704832 | ||
| Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. | Q33715284 | ||
| Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. | Q34311781 | ||
| Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features | Q34450428 | ||
| Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score | Q34450910 | ||
| Prevalence of monoclonal gammopathy of undetermined significance | Q34506801 | ||
| Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study | Q34608501 | ||
| Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular an | Q34610169 | ||
| International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Q34884527 | ||
| Kidney dysfunction during lenalidomide treatment for AL amyloidosis. | Q35025410 | ||
| Review of 1027 patients with newly diagnosed multiple myeloma | Q35045634 | ||
| Amyloidosis: pathogenesis and new therapeutic options. | Q35111771 | ||
| High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement | Q35750326 | ||
| Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis | Q36015183 | ||
| Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial | Q36163205 | ||
| Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma | Q36624286 | ||
| The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature | Q36633633 | ||
| Transplantation for amyloidosis | Q36726168 | ||
| Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements | Q36910372 | ||
| Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs | Q36950813 | ||
| Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). | Q37045900 | ||
| Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis | Q37172003 | ||
| Laryngeal amyloidosis causing hoarseness and airway obstruction | Q37359127 | ||
| Cardiac amyloidosis in a patient with multiple myeloma: a case report and review of literature. | Q37379828 | ||
| Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review | Q37546357 | ||
| Currents concepts on the immunopathology of amyloidosis | Q37559384 | ||
| Cardiac amyloidosis: approaches to diagnosis and management | Q37654514 | ||
| Echocardiographic evaluation of cardiac amyloid | Q37738051 | ||
| Treatment of immunoglobulin light chain amyloidosis | Q37738576 | ||
| Pitfalls in the diagnosis of primary amyloidosis | Q37761568 | ||
| Systemic amyloidosis: a challenge for the rheumatologist | Q37763504 | ||
| Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: a single center experience | Q37767014 | ||
| Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature | Q37774301 | ||
| Molecular imaging of amyloidosis: will the heart be the next target after the brain? | Q37970935 | ||
| Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation | Q39128093 | ||
| Serum uric acid: novel prognostic factor in primary systemic amyloidosis | Q40117481 | ||
| Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib | Q42847216 | ||
| Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study | Q42931881 | ||
| Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. | Q43050098 | ||
| Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis | Q43189700 | ||
| Amyloid in bone marrow smears of patients affected by multiple myeloma | Q43247364 | ||
| Thalidomide: a step forward in the treatment of malignant monoclonal gammopathies. | Q44388184 | ||
| Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. | Q44468671 | ||
| New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes | Q44572498 | ||
| End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. | Q44907517 | ||
| Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis | Q44960748 | ||
| Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation | Q45896840 | ||
| Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide | Q46380099 | ||
| Nodular senile pulmonary amyloidosis: a unique case confirmed by immunohistochemistry, mass spectrometry, and genetic study | Q46764637 | ||
| Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease | Q46775156 | ||
| Bortezomib in the treatment of AL amyloidosis: targeted therapy? | Q46892406 | ||
| Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis | Q46904469 | ||
| Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect | Q47895749 | ||
| Glycosaminoglycans are part of amyloid fibrils: ultrastructural evidence in avian AA amyloid stained with cuprolinic blue and labeled with immunogold. | Q50479496 | ||
| Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. | Q50526227 | ||
| Prevalence and origin of amyloid in kidney biopsies. | Q50604623 | ||
| Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. | Q51033339 | ||
| Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. | Q51954022 | ||
| Amyloid in endomyocardial biopsies. | Q52904497 | ||
| Prognostic significance of strain Doppler imaging in light-chain amyloidosis. | Q53066780 | ||
| Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. | Q53504425 | ||
| Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. | Q53671959 | ||
| Treatment of "primary" renal amyloidosis with melphalan. | Q54196552 | ||
| High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis | Q57218202 | ||
| A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis | Q57904446 | ||
| Cardiac changes in systemic amyloidosis: Visualisation by magnetic resonance imaging | Q58009561 | ||
| Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide | Q58030111 | ||
| Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine | Q58030328 | ||
| Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis | Q58030485 | ||
| Renal Transplantation in Systemic Amyloidosis-Importance of Amyloid Fibril Type and Precursor Protein Abundance | Q58853072 | ||
| Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival | Q58853078 | ||
| Outcome in Renal AL Amyloidosis After Chemotherapy | Q58853111 | ||
| High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis | Q58853165 | ||
| Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis | Q58853178 | ||
| Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report | Q60976607 | ||
| High-Dose Chemotherapy with Autotransplantation in AL Amyloidosis: A Flawed Meta-analysis | Q60976621 | ||
| Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response | Q60976697 | ||
| A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis | Q63413669 | ||
| A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine | Q73247899 | ||
| Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it | Q79765776 | ||
| Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone | Q81762674 | ||
| Left ventricular hypertrophy: cardiac magnetic resonance may help differentiate amyloidosis from hypertrophic cardiomyopathy | Q82831169 | ||
| Primary localized cutaneous amyloidosis: a sign of immune dysregulation? | Q83589494 | ||
| Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement | Q84019269 | ||
| Bladder amyloidosis | Q84077354 | ||
| I don't know how to treat amyloidosis | Q84617604 | ||
| Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis | Q84990268 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 416-25 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | American Journal of Hematology | Q4744246 |
| P1476 | title | Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment | |
| P478 | volume | 88 |
| Q58087715 | Amyloidosis of the Upper Aerodigestive Tract: Management of a Rare Disease and Review of the Literature |
| Q40918755 | Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement |
| Q35834954 | Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience |
| Q41448448 | Clinicopathological features of renal amyloidosis: a single-center study on 47 cases |
| Q40979010 | Combination of lenalidomide and low-dose dexamethasone therapy promotes the anticoagulant activity of warfarin in patients with immunoglobulin light-chain amyloidosis |
| Q38172998 | Future directions in the clinical management of amyloid light-chain amyloidosis |
| Q93052569 | Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency |
| Q35081363 | Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial |
| Q35820992 | Insight into the Protein Composition of Immunoglobulin Light Chain Deposits of Eyelid, Orbital and Conjunctival Amyloidosis. |
| Q36862056 | Isolated intracerebral light chain deposition disease: novel imaging and pathologic findings |
| Q36384308 | Laryngeal amyloidosis: diagnosis, pathophysiology and management |
| Q38556941 | Light Chain (AL) Amyloidosis: The Journey to Diagnosis |
| Q45870533 | Light-chain amyloidosis presenting as a change in bleeding phenotype in a patient with mild haemophilia A. |
| Q89800743 | Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome |
| Q41575087 | Localized amyloidosis of the upper gingiva: a case report |
| Q37035201 | Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience |
| Q37570615 | Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis |
| Q35156344 | Mid-infrared free-electron laser tuned to the amide I band for converting insoluble amyloid-like protein fibrils into the soluble monomeric form |
| Q64105650 | Multiorgan involvement by amyloid light chain amyloidosis |
| Q38250214 | Neuroarthropathy of the foot revealing primary systemic amyloidosis: case report and literature review. |
| Q38259728 | Pathophysiology and treatment of cardiac amyloidosis |
| Q47160869 | Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples |
| Q37593524 | The burden of amyloid light chain amyloidosis on health-related quality of life |
| Q35026460 | The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients |
| Q47228766 | The long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency |
| Q37375492 | Thermal stability threshold for amyloid formation in light chain amyloidosis |
| Q41046690 | Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox? |
| Q52981600 | Treatment of hepatic amyloid light-chain amyloidosis with bortezomib and dexamethasone in a liver transplant patient. |
| Q38759595 | siRNA targeting the κ light chain constant region: preclinical testing of an approach to nonfibrillar and fibrillar light chain deposition diseases |
Search more.